| Date | Time | Source | Headline | Symbol | Company |
| 05/24/2011 | 8:30PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/16/2011 | 5:23PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:53PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:52PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:52PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:51PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:51PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:50PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:49PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:48PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/13/2011 | 4:46PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/11/2011 | 9:00AM | Business Wire | Impax Laboratories Announces Voting Results from 2011 Annual Meeting of Stockholders | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/10/2011 | 8:30AM | Business Wire | Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159 | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/06/2011 | 5:00PM | Business Wire | Impax Laboratories Confirms Patent Suit Relating to Generic Concerta® 18, 27 and 36 mg Tablets | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/06/2011 | 4:14PM | Dow Jones News | CORRECT: Attention Disorder Drug Shortage Prompts Finger-Pointing Between Shire, Feds | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/06/2011 | 10:00AM | Business Wire | Impax Laboratories to Present at the Bank of America Merrill Lynch 2011 Health Care Conference | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/05/2011 | 4:27PM | Dow Jones News | Attention Disorder Drug Shortage Prompts Finger-Pointing Between Shire, Feds | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/03/2011 | 10:12AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/03/2011 | 7:00AM | Business Wire | Impax Laboratories Reports First Quarter 2011 Financial Results | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/02/2011 | 11:32AM | Zacks | Revenues Rise at Shire - Analyst Blog | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 05/02/2011 | 10:30AM | Business Wire | Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 04/14/2011 | 1:00PM | Business Wire | Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2011 Financial Results | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 04/11/2011 | 9:00AM | Business Wire | Impax Laboratories Confirms Patent Challenge Relating to OXYCONTIN® 10, 15, 20, 30, 40, 60, and 80 mg | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 04/08/2011 | 8:00AM | Business Wire | Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 04/04/2011 | 1:00PM | Business Wire | Impax Laboratories Confirms Patent Challenge Relating to DEXILANT® Delayed-Release Capsules, 30 mg and 60 mg | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 04/01/2011 | 9:00AM | Business Wire | Data on IPX066 APEX-PD Phase III Study for the Treatment of Early Parkinson’s Disease to be Presented at the American Acade... | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 03/31/2011 | 4:41PM | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 03/18/2011 | 4:01PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 03/15/2011 | 8:46AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |
| 03/14/2011 | 4:01PM | Business Wire | IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of Advanced Parkinson’s Disease | NASDAQ:IPXL | Impax Laboratories, Inc. (delisted) |